RHYTHM PHARMACEUTICALS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
222 BERKELEY STREET, BOSTON, MA, 02116
Mailing Address
222 BERKELEY STREET, BOSTON, MA, 02116
Phone
857-264-4280
Fiscal Year End
1231
EIN
462159271
Financial Overview
FY2025
$480.20M
Total Assets
$264.26M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 3 Initial insider ownership report | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 8-K Current report of material events | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
Annual Reports
10-K
February 26, 2026
- IMCIVREE product revenue grew 50% year-over-year, demonstrating strong market penetration.
- Successfully raised $250 million, bolstering cash reserves to $400 million for future operations.
Material Events
8-K
Strategy Change
March 16, 2026
High Impact
- Setmelanotide showed statistically significant and clinically meaningful BMI reductions in two specific patient populations: POMC/PCSK1 Heterozygous (Hets) Deficiency and SRC1 (NCOA1) Deficiency.
- Rhythm Pharmaceuticals will refine its strategic focus, prioritizing regulatory approvals for Setmelanotide in these specific, high-potential subgroups.
Insider Trading
STRONG SELL
3 insiders
25 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.